Fosamax Osteonecrosis of the Jaw Causation: How Fosamax Triggers Osteonecrosis of the Jaw Pathophysiology

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Communication to Occupational Exposure Context

General health and science communication has long served as a bridge between complex biomedical research and public understanding, emphasizing prevention and informed decision-making. Within this legacy, the discussion of medication side effects has been a cornerstone, particularly regarding how therapeutic interventions may carry unintended risks. This foundational context naturally extends to the domain of mass production and occupational health, where the focus shifts from patient-centered pharmacology to workplace exposure dynamics. In transitioning from general health information to an occupational exposure concern, one must consider how a widely prescribed therapeutic agent—originally developed for bone density management—becomes a focus of industrial hygiene. The pivot occurs when the same compound, manufactured and handled in large quantities, presents distinct exposure pathways for workers. This reframing moves the narrative from individual patient risk to population-level occupational safety, where the primary question is not about therapeutic benefit but about the conditions under which exposure occurs during production, packaging, or disposal. Thus, the heritage of general health communication provides the necessary vocabulary and conceptual framework to address how a substance’s biological activity, once understood in a clinical setting, informs risk assessment in manufacturing environments. The transition is seamless: from educating about medication effects to evaluating how those same effects might manifest through occupational contact, without invoking specific disease mechanisms.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health communication, we now focus on Fosamax (alendronate sodium), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism of action involves inhibiting bone resorption by osteoclasts, which reduces bone turnover. However, this same pharmacological activity has been linked to a serious adverse effect: osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. It can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing, and has been reported in patients taking bisphosphonates, including FOSAMAX (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The pathophysiology of how Fosamax triggers ONJ involves a complex interplay of drug-induced suppression of bone remodeling, local anatomical factors, and precipitating events.

Pathophysiology of Fosamax-Induced Osteonecrosis of the Jaw

The jawbone has unique characteristics that make it particularly susceptible to bisphosphonate-related complications. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including postmenopausal osteoporosis and bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Research using animal models has examined the effects of bisphosphonate treatment on jawbone properties. In a study using estrogen-deficient rats, treatments of bisphosphonate (alendronate), parathyroid hormone, and their combination were assessed for effects on the jawbone. The study involved multiscale characterization including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). These findings suggest that bisphosphonate therapy alters the mechanical and material properties of jawbone, potentially predisposing it to necrosis. The mechanistic pathway linking Fosamax to ONJ begins with the drug's potent inhibition of osteoclast-mediated bone resorption. Osteoclasts are essential for normal bone turnover, including the repair of microdamage and the remodeling of bone in response to mechanical stress. In the jaw, which undergoes constant remodeling due to chewing forces and dental procedures, this suppression can lead to an accumulation of microdamage and a reduced capacity to heal. When a precipitating event such as tooth extraction, dental implant placement, or local infection occurs, the bone's ability to mount a healing response is compromised. The resulting non-healing exposed bone is the hallmark of ONJ.

Risk Factors and Clinical Evidence

Known risk factors for osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm varies considerably. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This wide range reflects the multifactorial nature of ONJ, where the drug creates a permissive environment for necrosis, but a triggering event is often required. In placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), indicating that ONJ is a relatively rare event in the osteoporosis treatment population.

Causation Considerations and Warning Adequacy

Causation considerations for affected patients are complex. While Fosamax is a recognized risk factor for ONJ, the condition can also occur spontaneously in individuals not taking bisphosphonates. The presence of known risk factors, such as dental procedures or cancer therapy, complicates the attribution of causation solely to the drug. However, the biological plausibility is supported by the drug's mechanism of action and the observation that a subset of patients had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting a temporal relationship between drug exposure and the condition. The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, describing its association with bisphosphonates, known risk factors, and the potential benefit of treatment discontinuation before invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of use has not been determined and that for patients at low-risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). These warnings provide clinicians with information to assess risk and manage patients accordingly.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the mechanism by which Fosamax causes osteonecrosis of the jaw?

Fosamax (alendronate) inhibits osteoclast-mediated bone resorption, suppressing normal bone turnover. In the jawbone, which undergoes constant remodeling, this leads to accumulation of microdamage and reduced healing capacity. When a precipitating event like tooth extraction occurs, the bone cannot heal properly, resulting in exposed, non-healing bone characteristic of ONJ.

What are the known risk factors for developing osteonecrosis of the jaw while taking Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). Longer duration of bisphosphonate use increases risk.

How long after starting Fosamax can osteonecrosis of the jaw occur?

The time to onset of symptoms varies widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability reflects the multifactorial nature of ONJ, often requiring a triggering event.

Is osteonecrosis of the jaw a common side effect of Fosamax?

No, ONJ is a rare adverse effect. In placebo-controlled clinical studies of FOSAMAX, the percentages of patients with these symptoms were similar in the FOSAMAX and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.